Predictive Biosciences to Present at First Annual Boston Biotech R&D Conference

LEXINGTON, MA and SAN DIEGO, CA – October 22, 2008 – Predictive Biosciences, an emerging molecular diagnostics company developing non-invasive diagnostic products for informed cancer management™, today announced that Peter Klemm, Ph.D., president and chief executive officer of Predictive Biosciences, will present at the 2008 Boston Biotech R&D Conference, at 1:00PM on October 22, 2008 at Harvard Medical School. This conference will bring luminaries from top academic institutions who have been instrumental in establishing the strong Boston biotech community together with executives from several of the area’s most promising emerging biopharmaceutical companies and leaders from the venture capital community and equity markets.
  
“We are very pleased to be participating in the first annual Boston Biotech R & D conference,” said Dr. Klemm.  “We look forward to discussing our pipeline of innovative urine-based diagnostic assays designed to enable physicians to conveniently and reliably determine the presence or absence of cancer.”
 
About The Boston Biotech R&D Conference
The 2008 Boston Biotech R&D Conference will take place at Harvard Medical School and will highlight the work of top academics as well as up-and-coming biotech companies in the Boston area. The agenda features keynotes from several luminaries in medicine and research, including Jeffrey S. Flier, Dean of Harvard Medical School,   Leonard Guarente, Ronald Kahn, Eric S. Lander, Robert Langer, Phillip Sharp, David Sinclair, as well as CEOs of the next generation of leading biotech and pharma companies from the Boston area. The conference is sponsored by Alexandria Real Estate Equities Inc., Pure Communications Inc., and Rodman & Renshaw, LLC.  For more information, visit www.bostonbiotechconference.com.

About Predictive Biosciences

Leveraging its portfolio of patented biomarkers and clinical algorithms, Predictive Biosciences is pioneering intervention diagnostic assays for informed cancer management™.  Predictive Biosciences’ tests will enable physicians to reliably determine the presence or absence of cancer.  This information, incorporated into current standard clinical practice, should lead to more effective utilization of existing diagnostic tools and ultimately better outcomes for patients.  Predictive Biosciences’ first assays are designed to detect urinary biomarkers fundamentally associated with the physiological changes resulting from cancer development and progression.  The initial focus for these tests will be the growing cancer survivor population and the large number of individuals undergoing clinical workups for cancer.  Predictive Biosciences was launched in 2006 and is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates.  For more information and partnership inquiries, visit Predictive Biosciences’ website at www.predictivebiosci.com.

###

Contacts:        

Sondra Newman
Pure Communications, Inc.
617-877-5687

Download this Press Release as a pdf file.